Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates

PLoS Pathogens

Volumn 7, Issue 11, 2011, Pages

  Weinfurter, Jason T ^a,b   Brunner, Kevin ^a   Capuano III, Saverio V ^a   Li, Chengjun ^b   Broman, Karl W ^c   Kawaoka, Yoshihiro ^b,d,e   Friedrich, Thomas C ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; GAMMA INTERFERON; KI 67 ANTIGEN;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; INFLUENZA VIRUS A H1N1; LOWER RESPIRATORY TRACT INFECTION; LUNG; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PHENOTYPE; PRIMATE; SEASONAL INFLUENZA; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION; VIRAL CLEARANCE; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD38; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; CYTOKINES; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; KI-67 ANTIGEN; LUNG; MACACA MULATTA; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES;

ANIMALIA; MACACA MULATTA; ORTHOMYXOVIRIDAE; PRIMATES;

EID: 81755177734     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002381     Document Type: Article

References (73)

1. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, et al. (2009) Pandemic potential of a strain of influenza A (H1N1): early findings. Science 324: 1557-1561.
2. Neumann G, Noda T, Kawaoka Y, (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931-939.
3. US Centers for Disease Control and Prevention (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 58: 521-524.
4. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-1952.
5. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
6. Cohen J, (2009) Public health. A race against time to vaccinate against novel H1N1 virus. Science 325: 1328-1329.
7. Effros RB, Doherty PC, Gerhard W, Bennink J, (1977) Generation of both cross-reactive and virus-specific T-cell populations after immunization with serologically distinct influenza A viruses. J Exp Med 145: 557-568.
8. Yetter RA, Lehrer S, Ramphal R, Small PAJ, (1980) Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun 29: 654-662.
9. Zweerink HJ, Courtneidge SA, Skehel JJ, Crumpton MJ, Askonas BA, (1977) Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses. Nature 267: 354-356.
10. Yap KL, Ada GL, McKenzie IF, (1978) Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 273: 238-239.
11. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, et al. (2007) Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25: 612-620.
12. Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, et al. (2010) Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 202: 1011-1020.
13. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ, (2011) T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol 85: 448-455.
14. Epstein SL, (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49-53.
15. McMichael AJ, Gotch FM, Noble GR, Beare PA, (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17.
16. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, et al. (2009) Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 106: 20365-20370.
17. Assarsson E, Bui HH, Sidney J, Zhang Q, Glenn J, et al. (2008) Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol 82: 12241-12251.
18. Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478-3490.
19. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, et al. (2010) Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci U S A 107: 12599-12604.
20. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, et al. (2006) T cell responses are better correlates of vaccine protection in the elderly. J Immunol 176: 6333-6339.
21. Cilloniz C, Shinya K, Peng X, Korth MJ, Proll SC, et al. (2009) Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog 5: e1000604.
22. Fan S, Gao Y, Shinya K, Li CK, Li Y, et al. (2009) Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates. PLoS Pathog 5: e1000409.
23. Baskin CR, Bielefeldt-Ohmann H, Tumpey TM, Sabourin PJ, Long JP, et al. (2009) Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A 106: 3455-3460.
24. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, et al. (2009) Recombinant Modified Vaccinia Virus Ankara Expressing the Hemagglutinin Gene Confers Protection against Homologous and Heterologous H5N1 Influenza Virus Infections in Macaques. J Infect Dis 199: 405-413.
25. Carroll TD, Matzinger SR, Genesca M, Fritts L, Colon R, et al. (2008) Interferon-induced expression of MxA in the respiratory tract of rhesus macaques is suppressed by influenza virus replication. J Immunol 180: 2385-2395.
26. Rimmelzwaan GF, Baars M, van Beek R, van Amerongen G, Lovgren-Bengtsson K, et al. (1997) Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol 78: 757-765.
27. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, et al. (2003) A primate model to study the pathogenesis of influenza A (H5N1) virus infection. Avian Dis 47: 931-933.
28. Baas T, Baskin CR, Diamond DL, Garcia-Sastre A, Bielefeldt-Ohmann H, et al. (2006) Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J Virol 80: 10813-10828.
29. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, et al. (2007) Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445: 319-323.
30. Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, et al. (2009) Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 83: 4624-4630.
31. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA, et al. (2001) Pathogenesis of influenza A (H5N1) virus infection in a primate model. J Virol 75: 6687-6691.
32. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, et al. (2008) Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167: 775-785.
33. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
34. Shinya K, Ebina M, Yamada S, Ono M, Kasai N, et al. (2006) Avian flu: influenza virus receptors in the human airway. Nature 440: 435-436.
35. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, et al. (2006) H5N1 Virus Attachment to Lower Respiratory Tract. Science 312: 399.
36. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, et al. (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: 63-73.
37. Grebe KM, Yewdell JW, Bennink JR, (2008) Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect 10: 1024-1029.
38. Brown DM, Dilzer AM, Meents DL, Swain SL, (2006) CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol 177: 2888-2898.
39. Rimmelzwaan GF, Fouchier RA, Osterhaus AD, (2007) Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 18: 529-536.
40. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, et al. (2006) CD4+ T-cell memory: generation and multi-faceted roles for CD4+ T cells in protective immunity to influenza. Immunol Rev 211: 8-22.
41. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW, (2001) Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166: 7381-7388.
42. Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, et al. (2011) Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 17: 195-199.
43. McGill J, Legge KL, (2009) Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J Immunol 183: 4177-4181.
44. Lawrence CW, Ream RM, Braciale TJ, (2005) Frequency, specificity, and sites of expansion of CD8+ T cells during primary pulmonary influenza virus infection. J Immunol 174: 5332-5340.
45. Herfst S, van den Brand JMA, Schrauwen EJA, de Wit E, Munster VJ, et al. (2010) Pandemic 2009 H1N1 influenza virus causes diffuse alveolar damage in cynomolgus macaques. Vet Pathol 47: 1040-1047.
46. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, et al. (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470: 543-547.
47. Schwartz JA, Buonocore L, Suguitan A, Hunter M, Marx PA, et al. (2011) Vesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques. J Virol 85: 4602-4605.
48. Heldens JGM, Glansbeek HL, Hilgers LAT, Haenen B, Stittelaar KJ, et al. (2010) Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits. Vaccine 28: 8125-8131.
49. Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, et al. (2010) Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 82: 1754-1761.
50. Itoh Y, Ozaki H, Ishigaki H, Sakoda Y, Nagata T, et al. (2010) Subcutaneous inoculation of a whole virus particle vaccine prepared from a non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic avian influenza virus in cynomolgus macaques. Vaccine 28: 780-789.
51. Loudon PT, Yager EJ, Lynch DT, Narendran A, Stagnar C, et al. (2010) GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 5: e11021.
52. Carroll TD, Matzinger SR, Barro M, Fritts L, McChesney MB, et al. (2010) Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone((R)) in rhesus macaques. Vaccine 29: 931-940.
53. Lay M, Callejo B, Chang S, Hong DK, Lewis DB, et al. (2009) Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine 27: 3811-3820.
54. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, et al. (2009) Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 27: 6296-6299.
55. Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, et al. (2008) Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3: e2517.
56. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD, (2008) Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 82: 2565-2569.
57. Itoh Y, Ozaki H, Tsuchiya H, Okamoto K, Torii R, et al. (2008) A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26: 562-572.
58. Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, et al. (2011) Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 203: 158-167.
59. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, et al. (2010) Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 84: 6527-6535.
60. Kreijtz J, de Mutsert G, van Baalen C, Fouchier R, Osterhaus A, et al. (2008) Cross-recognition of avian H5N1 influenza virus by human cytotoxic T lymphocyte populations directed to human influenza A virus. J Virol 82: 5161-5166.
61. Scheible K, Zhang G, Baer J, Azadniv M, Lambert K, et al. (2011) CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine 29: 2159-2168.
62. Kohlmeier JE, Woodland DL, (2009) Immunity to respiratory viruses. Annu Rev Immunol 27: 61-82.
63. Terajima M, Cruz J, Leporati AM, Orphin L, Babon JAB, et al. (2008) Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients. J Virol 82: 9283-9287.
64. Subbramanian RA, Basha S, Shata MT, Brady RC, Bernstein DI, (2010) Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 28: 8258-8267.
65. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, et al. (2006) Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80: 11756-11766.
66. Co MDT, Orphin L, Cruz J, Pazoles P, Green KM, et al. (2009) In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 27: 319-327.
67. Rimmelzwaan GF, Kreijtz JHCM, Bodewes R, Fouchier RAM, Osterhaus ADME, (2009) Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine 27: 6363-6365.
68. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, et al. (2011) Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1-7.
69. US National Research Council (1996) Guide for the care and use of laboratory animals. Washington, D.C. National Academy Press.
70. Weatherall D, (2006) The use of non-human primates in research: A working group report. Final Report December 2006 FRS FMedSci pp. 152 p.
71. Kaizu M, Borchardt GJ, Glidden CE, Fisk DL, Loffredo JT, et al. (2007) Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 59: 693-703.
72. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, et al. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96: 9345-9350.
73. World Health Organization (2002) WHO Manual on Animal Influenza Diagnosis and Surveillance. Geneva World Health Organization Press.